Abstract:BACKGROUND: Patients with mass-forming pancreatitis (MFP) or pancreatic ductal adenocarcinoma (PDAC) presented similar clinical symptoms, but required different treatment approaches and had different survival outcomes. This meta-analysis aimed to compare the diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT) in differentiating MFP from PDAC, and to compare the two modalities.METHODS: A literature search was performed in the PubMed, EMBASE (Ovid), Cochrane Library (CENTRAL), CNKI, VIP, and WanFang databases to identify original studies published from inception to August 20, 2021. Studies reporting the diagnostic performances of CEUS and CECT for differentiating MFP from PDAC were included. The meta-analysis was performed with Stata 15.0 software. The outcomes included the pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (-LR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) curves of CEUS and CECT. Meta-regression was conducted to investigate heterogeneity. Bayesian network meta-analysis was conducted to indirectly compare the overall diagnostic performance.RESULTS: Twenty-six studies with 2115 pancreatic masses were included. The pooled sensitivity and specificity of CEUS for MFP were 82% (95% confidence interval [CI], 73%-88%; I2 = 0.00%) and 95% (95% CI, 90%-97%; I2 = 63.44%), respectively; the overall +LR, -LR, and DOR values were 15.12 (95% CI, 7.61-30.01), 0.19 (95% CI, 0.13-0.29), and 78.91 (95% CI, 30.94-201.27), respectively; and the area under the SROC curve (AUC) was 0.90 (95% CI, 0.87-92). However, the overall sensitivity and specificity of CECT were 81% (95% CI, 75-85%; I2 = 66.37%) and 94% (95% CI, 90-96%; I2 = 74.87%); the overall +LR, -LR, and DOR values were 12.91 (95% CI, 7.86-21.20), 0.21 (95% CI, 0.16-0.27), and 62.53 (95% CI, 34.45-113.51), respectively; and, the SROC AUC was 0.92 (95% CI, 0.90-0.94). The overall diagnostic accuracy of CEUS was comparable to that of CECT for the differential diagnosis of MFP and PDAC (relative DOR 1.26, 95% CI [0.42-3.83], P > 0.05).CONCLUSIONS: CEUS and CECT have comparable diagnostic performance for differentiating MFP from PDAC, and should be considered as mutually complementary diagnostic tools for suspected focal pancreatic lesions.

Differentiation of Pancreatic Ductal Adenocarcinoma from Inflammatory Mass: Added Value of Magnetic Resonance Elastography.

Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation

Comparison of Double Contrast-Enhanced Ultrasound and MDCT for Assessing Vascular Involvement of Pancreatic Adenocarcinoma: Preliminary Results Correlated with Surgical Findings

Differentiation of Pancreatic Neuroendocrine Carcinoma from Pancreatic Ductal Adenocarcinoma Using Magnetic Resonance Imaging: the Value of Contrast-Enhanced and Diffusion Weighted Imaging

Comparative Diagnostic Evaluation with Contrast-Enhanced Ultrasound, Computed Tomography and Magnetic Resonance Imaging in Patients with Pancreatic Cystic Neoplasms

Assessment of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Differentiation of Pancreatic Ductal Adenocarcinoma from Other Pancreatic Solid Lesions.

Differentiation of Chronic Mass-Forming Pancreatitis from Pancreatic Ductal Adenocarcinoma Using Contrast-Enhanced Computed Tomography.

Contrast-enhanced ultrasound and contrast-enhanced computed tomography for differentiating mass-forming pancreatitis from pancreatic ductal adenocarcinoma: a meta-analysis

Multimodel Magnetic Resonance Imaging of Mass-Forming Autoimmune Pancreatitis: Differential Diagnosis with Pancreatic Ductal Adenocarcinoma

Differentiation of Pancreatic Carcinoma and Mass-Forming Focal Pancreatitis: Qualitative and Quantitative Assessment by Dynamic Contrast-Enhanced MRI Combined with Diffusion-Weighted Imaging

Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma: CT and MR imaging for differentiation

Investigating the Value of Dual-Layer Spectral Detector CT in Distinguishing Resectable Pancreatic Ductal Adenocarcinoma from Mass-Forming Chronic Pancreatitis

CT Enhancement Scanning and Diffusion-Weighted Magnetic Resonance Imaging for Differential Diagnosis Between Chronic Mass-Forming Pancreatitis and Pancreatic Carcinoma

Multitasking dynamic contrast enhanced magnetic resonance imaging can accurately differentiate chronic pancreatitis from pancreatic ductal adenocarcinoma

Development and Validation of a Novel Model Incorporating MRI-based Radiomics Signature with Clinical Biomarkers for Distinguishing Pancreatic Carcinoma from Mass-Forming Chronic Pancreatitis.

Multiparametric Mapping Magnetic Resonance Imaging of Pancreatic Disease

CMAR_A_217033 7857..7866

Is the radiomics-clinical combined model helpful in distinguishing between pancreatic cancer and mass-forming pancreatitis?

Diagnostic Accuracy of Unenhanced CT Texture Analysis to Differentiate Mass-Forming Pancreatitis from Pancreatic Ductal Adenocarcinoma

Non-enhanced Magnetic Resonance Imaging-Based Radiomics Model for the Differentiation of Pancreatic Adenosquamous Carcinoma from Pancreatic Ductal Adenocarcinoma

Magnetic resonance elastography and T1 mapping for early diagnosis and classification of chronic pancreatitis